Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Bcyc are up

<< Previous

Bullboard Posts

Next >>

Comment by Wino115on Oct 07, 2021 5:49pm

124 Views

Post# 33986531

RE:Bcyc are up

This is a very good template for THTX management to look at when they need to construct their initial thoughts and put it in a PR. This is a PDC doing something very similar, except different receptor targets and drugs. They have the advantage of numerous concurrent trials, but just this intro you could (if we see it) substitute THTX's platform! Done...no need to hire PR firm.

"These data support our belief that the Bicycle Theratech SORT1 platform offers a potentially differentiated approach to traditional toxin delivery. The data generated from these molecules provide a wealth of information and insights as we continue to expand the application of our technology and generate additional Bicycle-SORT1-targeted therapeutics with the intention of making a meaningful difference to cancer patients,” said Kevin Lee, Ph.D., Chief Executive Officer of Bicycle Therapeutics Paul Leveuque CEO of THeratechnologies. “We look forward to providing additional clinical data on BT5528 and BT8009 TH1902 and new molecules in the SORT1 program next year, and initiating continuing our Phase I/II study for BT7480 TH1902 in 2022 later this year.”

qwerty22 wrote: On Ph1 data. They've been going up for a month of so and a nice jump on this news. They even did a short halt.

https://stockhouse.com/news/press-releases/2021/10/07/bicycle-therapeutics-announces-interim-bt5528-phase-i-clinical-trial-results-and

<< Previous

Bullboard Posts

Next >>

From now on, dynaCERT instead of Bitcoin or NVIDIA?